Free Trial

Halozyme Therapeutics (HALO) Competitors

$42.76
-0.32 (-0.74%)
(As of 04:00 PM ET)

HALO vs. CBPO, MNTA, IOVA, TWST, NVAX, ALNY, NBIX, BMRN, INCY, and UTHR

Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Novavax (NVAX), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.

Halozyme Therapeutics vs.

Halozyme Therapeutics (NASDAQ:HALO) and China Biologic Products (NASDAQ:CBPO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.

Halozyme Therapeutics has higher revenue and earnings than China Biologic Products. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$829.25M6.56$281.59M$2.4217.67
China Biologic Products$503.70M9.38$138.81M$4.2828.04

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 2.7% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 2.7% of China Biologic Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 36.94% compared to China Biologic Products' net margin of 27.43%. Halozyme Therapeutics' return on equity of 225.71% beat China Biologic Products' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics36.94% 225.71% 20.52%
China Biologic Products 27.43%8.32%7.64%

Halozyme Therapeutics presently has a consensus price target of $53.14, suggesting a potential upside of 24.95%. Given Halozyme Therapeutics' higher possible upside, equities analysts clearly believe Halozyme Therapeutics is more favorable than China Biologic Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
China Biologic Products
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Halozyme Therapeutics received 152 more outperform votes than China Biologic Products when rated by MarketBeat users. Likewise, 69.19% of users gave Halozyme Therapeutics an outperform vote while only 60.21% of users gave China Biologic Products an outperform vote.

CompanyUnderperformOutperform
Halozyme TherapeuticsOutperform Votes
503
69.19%
Underperform Votes
224
30.81%
China Biologic ProductsOutperform Votes
351
60.21%
Underperform Votes
232
39.79%

Halozyme Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

In the previous week, Halozyme Therapeutics had 10 more articles in the media than China Biologic Products. MarketBeat recorded 10 mentions for Halozyme Therapeutics and 0 mentions for China Biologic Products. Halozyme Therapeutics' average media sentiment score of 0.67 beat China Biologic Products' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Halozyme Therapeutics Positive
China Biologic Products Neutral

Summary

Halozyme Therapeutics beats China Biologic Products on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$5.39B$2.81B$4.96B$8.05B
Dividend YieldN/A2.85%2.80%3.97%
P/E Ratio17.5013.21139.1615.77
Price / Sales6.50309.872,450.0972.66
Price / Cash13.79168.7934.6931.30
Price / Book30.246.845.474.57
Net Income$281.59M-$47.92M$104.51M$213.29M
7 Day Performance-6.90%-5.15%-0.92%-1.13%
1 Month Performance9.21%1.09%2.20%2.17%
1 Year Performance27.53%1.53%4.92%6.99%

Halozyme Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CBPO
China Biologic Products
0 of 5 stars
$119.99
+1.7%
N/A+0.0%$4.72B$503.70M33.522,269
MNTA
Momenta Pharmaceuticals
0 of 5 stars
$52.48
flat
N/AN/A$6.25B$23.87M-24.75131
IOVA
Iovance Biotherapeutics
4.3955 of 5 stars
$9.70
-3.1%
$24.64
+154.0%
+28.5%$2.71B$1.90M-5.39557Gap Up
TWST
Twist Bioscience
2.5817 of 5 stars
$42.44
+0.5%
$42.50
+0.1%
+194.5%$2.47B$245.11M-12.63919Positive News
Gap Down
NVAX
Novavax
3.8761 of 5 stars
$15.52
+0.1%
$17.50
+12.8%
+115.2%$2.18B$983.71M-4.891,543Gap Down
ALNY
Alnylam Pharmaceuticals
4.538 of 5 stars
$150.06
+1.6%
$216.19
+44.1%
-20.3%$18.98B$1.83B-55.992,100Positive News
NBIX
Neurocrine Biosciences
4.7345 of 5 stars
$140.48
+0.8%
$148.96
+6.0%
+54.0%$14.14B$1.89B38.701,400Analyst Forecast
News Coverage
Positive News
Gap Down
BMRN
BioMarin Pharmaceutical
4.963 of 5 stars
$74.43
-1.4%
$106.11
+42.6%
-15.9%$14.13B$2.42B69.563,401
INCY
Incyte
4.9702 of 5 stars
$57.25
-0.1%
$73.69
+28.7%
-8.5%$12.85B$3.70B17.352,524Short Interest ↓
UTHR
United Therapeutics
4.7884 of 5 stars
$269.15
-1.4%
$309.44
+15.0%
+29.8%$11.94B$2.50B12.731,168Insider Selling

Related Companies and Tools

This page (NASDAQ:HALO) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners